Article Information
History
- January 7, 2022.
Article Versions
- Version 1 (January 6, 2022 - 20:42).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Amrita K Cheema1,2,#,
- Yaoxiang Li1,
- Sean Collins3,
- Simeng Suy3,
- Mary Ventimiglia1,
- Keith Kowalczyk3,
- Ryan Hankins3,
- John Lynch3,
- Einsley-Marie Janowski4,
- Scott Grindrod5,
- Alejandro Villagra6 and
- Anatoly Dritschilo3
- 1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3900 Reservoir Road NW, Washington DC 20057
- 2Department of Biochemistry, Molecular and Cellular Biology, Georgetown University Medical Center, 3900 Reservoir Road NW, Washington DC 20057
- 3Department of Radiation Medicine, LL Bles, MedStar-Georgetown University Hospital, 3970 Reservoir Road NW, Washington DC 20007
- 4Department of Radiation Oncology, PO Box 800383, Charlottesville, VA 22908-0383
- 5Shuttle Pharmaceuticals, 1 Research Court, Suite 450 Rockville, MD 20850
- 6Department of Biochemistry and Molecular Medicine, George Washington Cancer Center, George Washington University, 2150 Pennsylvania Avenue NW, Washington, DC 20037
- ↵#Corresponding Author: Amrita K Cheema, Correspondence Address: GC2, Pre-clinical Science Building, 3900 Reservoir Road NW, Washington DC 20007, Email: akc27{at}georgetown.edu, Phone: 202-687-2756
Posted January 07, 2022.
Innate immune responses in patients treated with SBRT irradiation enhances prostate cancer remissions
